Lymphoma

For more than 20 years, we have been striving to make a difference for people with lymphoma where current treatment options are limited. Today, we continue to invest in developing innovative therapies that meet the unique needs of each and every patient, and give them the best outcomes following a lymphoma diagnosis.

Challenge

Lymphoma is a type of blood cancer that affects lymphocytes, a type of white blood cell essential to the body’s ability to fight infections. The most common type of lymphoma, found in 4 out of 5 patients is non-Hodgkin lymphoma (NHL), which can be further classified into aggressive (fast) and indolent (slow) growing subtypes of disease. 

With multiple subtypes, treatment and prognosis varies greatly. “Relapse” unfortunately is a well-known term for people with lymphoma, and with each relapse their prognosis worsens. Patients often live in fear of their cancer returning, which has a significant emotional and psychological impact – not just on them – but also on their families and friends.

Focus

Roche’s medicines have contributed to improving patient outcomes and advancing the treatment of lymphomas, with several considered the standard of care. Yet there is still progress to be made to help as many patients as possible to live longer, healthier lives.

Two of our key focus areas are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In DLBCL, we’re aiming to increase the likelihood of lasting response for people newly diagnosed with the disease and provide treatments that mitigate the chance of relapse. For FL, our goal is to help patients achieve long lasting remissions, even after multiple lines of therapy, and minimise the impact treatment has on their day-to-day life. 

To do this, we are working in partnership with the lymphoma community to re-define treatment standards. As well as pioneering new therapies we are looking at beyond-the-medicine solutions like supporting widespread access to treatments so that we can help as many people with lymphoma receive the best care possible.

M-NZ-00000731/MR9307/SEP2023

© 2024, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000625-v9.0/MR10105/MAR24. This site was last updated MAR2024

ContactDrug SafetyWorldwide LocationslinkedinfacebooktwitterinstagramyoutubePharma solutionsRoche careersRoche cancer treatmentsRoche diagnosticsRoche hubPrivacy statementLegal statement